Phase I dose escalation study with the Lewis Y carbohydrate specific humanized antibody IGN311 by Oruzio, Daniel et al.
Journal of Cancer Therapy, 2011, 2, 760-771 
doi:10.4236/jct.2011.25102 Published Online December 2011 (http://www.SciRP.org/journal/jct) 
Copyright © 2011 SciRes.                                                                                  JCT 
Phase I Dose Escalation Study with the Lewis Y 
Carbohydrate Specific Humanized Antibody 
IGN311 
Daniel Oruzio1, Günter Waxenecker2,3, Christoph Aulmann1, Bruno Märkl1, Theodor Wagner1,  
Geert Mudde2,4, Manfred Schuster2,5, Norbert Eller2,6, Andrea Mayer2,7, Stefan Stranner2,5,   
Gottfried Himmler2,8, Hans Loibner2,5, Günter Schlimok1, Ralf Kircheis2,9, Andreas Nechansky2,10* 
 
1Zentralklinikum, Augsburg, Germany; 2Igeneon, Vienna, Austria; 3AGES Pharmed, Vienna, Austria; 4S-TARget, Vienna, Austria; 
5Apeiron, Vienna, Austria; 6CDMS, Vienna, Austria; 7Immatics, Tübingen, Germany; 8f-Star, Vienna, Austria; 9ViroLogik, Erlangen, 
Germany; 10Meridian Biopharmaceuticals, Vienna, Austria. 
E-mail: *a.nechansky@meridian-biopharm.at 
 
Received October 3rd, 2011; revised November 6th, 2011; accepted November 16th, 2011. 
 
ABSTRACT 
Purpose: Investigation of safety, tolerability, pharmacokinetics, and anti-tumor activity of the Lewis Y-specific, fully 
humanized monoclonal antibody (mAb) IGN311 in patients with Lewis Y positive tumors in a Phase I clinical trial. Ex- 
perimental Design: Twelve patients (pts) were enrolled in an open-label, uncontrolled, dose escalating Phase I study. 
Three pts received 50 mg, three pts 100 mg and six pts 200 mg IGN311 by i.v. infusion on days 1 and 15. Blood samples 
were taken immediately before infusion, and 0.5, 4, 8, 24 hours post infusion, as well as on days 3, 5 and 8 after the first 
and second infusion, respectively, and day 29. A final visit was scheduled for day 43. Results: No drug related adverse 
events were observed in the 50 mg and 100 mg dose groups. Three out of six patients in the 200 mg dose group showed 
drug related adverse reactions with nausea, vomiting and hypotension in one patient (NCI CTC grade 3) being the dose 
limiting toxicities. t1/2 of IGN311 was ~20 days after second infusion of IGN311. Sera of patients receiving IGN311 
were capable of lysing Lewis Y positive tumor cells in vitro by both, complement-dependent cytotoxicity (CDC) and 
antibody-dependent cellular cytotoxicity (ADCC). Circulating tumor cells found in the peripheral blood in two out of 
twelve pts prior to treatment were reduced after treatment to below the quantification limit of the detection method. 
None of the patients showed an increase in the number of disseminated tumor cells during treatment period. Conclu- 
sions: The good safety and PK profile, the biological activity regarding CDC and ADCC mediated tumor cell lysis, and 
the elimination of circulating tumor cells warrant further clinical investigation of IGN311. 
 
Keywords: Passive Immunotherapy, Therapeutic Monoclonal Antibody, Disseminated Tumor Cells, Phase I Study, 
Lewis Y Carbohydrate, HAHA (Human Anti-Human Antibodies) 
1. Introduction 
Passive immunotherapy of cancer is based on the ad- 
ministration of antibodies or immune effector cells that 
have the ability to directly mediate anti-tumor responses. 
The humanized mAb IGN311 which is specific for the 
tumor-associated carbohydrate antigen Lewis Y. (LeY) 
has been developed for passive immunotherapy of pa- 
tients with LeY expressing tumors. The LeY antigen is 
expressed on the majority of human cancers of epithelial 
origin whereas expression on normal tissue is limited to 
epithelial cells of the esophagus, stomach, the proximal 
small intestine, some acinar cells of the pancreas and 
resting granulocytes [1-5]. Regarding the expression pro- 
file on tumor cells, predominantly adenocarcinomas of 
the lung, breast, colorectal, gastric, pancreatic, prostate 
and ovarian cancers have been tested positive for LeY 
[2,6-9]. Pronounced expression of LeY in different tu- 
mors is associated with decreased survival and higher 
metastatic potential [10-14]. 
Because LeY represents an attractive target for im- 
mune therapy, a variety of murine mAbs has been gener- 
ated against this carbohydrate antigen and their anti-tu- 
mor activities have been explored and have demonstrated 
anti-tumor activity in tumor cell models in vitro, animal 
models and clinical studies [1,2,6,15-22]. 
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Based on the promising effects found with murine 
mAbs, several LeY-specific humanized mAb have been 
designed with improved pharmacokinetics in humans 
[23-27]. Recently, a Phase I biodistribution and pharma- 
cokinetic trial with the humanized mAb Hu3s193 in pa- 
tients with LeY positive, advanced epithelial cancer has 
demonstrated selective targeting of tumors with no evi- 
dence of any consistent normal tissue uptake [26]. An- 
other promising humanized LeY specific mAb is the 
hABL364—designated IGN311—that is the humanized 
version of the murine mAb BR55-2 [1,6,15-17]. During 
humanization, the affinity to the target cells and the ef- 
fector functions were optimized by molecular modeling 
[23]. After pharmacological and toxicological studies in 
rhesus monkeys which have indicated favorable phar- 
macokinetic features of IGN311, a Phase I dose escala- 
tion study with IGN311 administered by intravenous 
infusion to patients with LeY expressing tumors was 
conducted. The primary objective of this study was to 
assess safety, tolerability and pharmacokinetics. As sec- 
ondary objective, anti-tumor activity and immunologic 
parameters were investigated.  
2. Patients and Methods 
2.1. Eligibility Criteria 
Male or female pts (aged between 18 and 80 years) with 
biopsy proven LeY positive carcinoma refractory to 
standard therapies were eligible for this phase I study. 
LeY expression was determined using formalin-fixed 
primary tissue. Pts with an anticipated life expectancy ≥4 
months and a Karnofsky Performance Score of ≥70 were 
included. The presence of at least one objective disease 
marker within the last 6 weeks prior to inclusion was 
obligatory. No other therapies for the treatment of carci- 
noma (e.g. chemotherapy, radiation, immune therapy or 
any investigational agent other than IGN311) during the 
study period and within 6 weeks prior to therapy with the 
exceptions of bisphosphonates and hormon therapy was 
to be administered. Informed consent from all pts was 
obtained before enrollment into the study.  
2.2. Study Design and Treatment 
The study was designed as an open-label, uncontrolled, 
dose escalating Phase I study, enrolling 12 evaluable pts. 
Pts received IGN311 intravenously during a two hour 
infusion on day 1 and 15 without pre-medication. Three 
pts were included for each dose level and had to be ex- 
tended by two additional patients in case of observed 
grade 3 toxicities. The first three evaluable pts received 
50 mg IGN311 per infusion (cohort I), the next three 
evaluable pts received 100 mg IGN311 per infusion (co- 
hort II) and five pts received 200 mg IGN311 per infu- 
sion (cohort III, because of grade 3 toxicities at this dose 
level). The only significant amendment to the original 
protocol was applied to pt 12 with regard to a prolonga- 
tion of the infusion time from 2 to 4 hours (cohort IV). 
Pts were under close monitoring of blood pressure, heart 
rate, respiratory rate, body temperature every 30 minutes 
during the infusion of IGN311 and 0.5, 1, 1.5, 3, 4 and 
8h post infusion. Blood samples were taken immediately 
before infusion, and 0.5, 4, 8, 24 hours post infusion, as 
well as on days 3, 5 and 8 after the first and second infu- 
sion, respectively, and days 29 and 43. The study was 
conducted in accordance with the latest revision of the 
Declaration of Helsinki, the requirements of Good Clini- 
cal Practice of the European Community (CPMP/ICH/ 
135195) and European Clinical Trials Directive 2001/ 
20/EC. Written, voluntary informed consent to partici- 
pate in this study was obtained prior to enrollment into 
the study and for performing of any study specific evalua- 
tions. The primary objectives of the study were to assess 
safety, tolerability and pharmacokinetics and to deter- 
mine dose limiting toxicity (DLT) and maximum-toler- 
ated dose (MTD) of intravenous infusions of two doses 
of IGN311 administered on day 1 and day 15 to pts with 
LeY expressing carcinomas. All drug related adverse 
events were classified using the NCI toxicity criteria. 
Safety evaluations included clinical and laboratory as- 
sessments (physical examination, vital signs, hematology, 
chemistry profile, urinalysis, ECG, and adverse events). 
The secondary objectives of the study were to monitor 
anti-tumor activity and immunological parameters. RE- 
CIST criteria were used to evaluate the tumor response 
using CT scans. Different tumor markers were measured. 
As surrogate parameter for tumor response the amount of 
disseminated tumor cells in peripheral blood was used 
[28-31]. Tumor assessments were performed at baseline 
and on day 43. 
2.3. Manufacturing IGN311 
IGN311 drug substance was produced according to GMP 
guidelines by BioInvent International AB (Lund, Swe- 
den). The final product was filled in glass syringes ac- 
cording to GMP guidelines at the Statens Serum Institute 
(Copenhagen, Denmark).  
2.4. Pharmacokinetics 
For pharmacokinetic analysis of IGN311, blood samples 
were taken before and 0.5, 4, 8, 24 hours after infusion, 
and on days 3, 5 and 8 after the first and second infusion. 
Additional blood samples were taken on days 29 and 43. 
Concentrations of IGN311 in the serum were measured 
using a specific sandwich ELISA with the anti-idiotypic 
mAb MMA383 specifically recognizing the idiotype of 
IGN311 [32]. Pharmacokinetic parameters were calcu- 
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lated [33] separately for each of the two infusions: The 
area under the concentration-time curve (AUC 0-t) was 
calculated from the original data using the trapezoidal 
rule. Kel (slope) was fitted using the log-transformed last 
three measurements of infusion 1 or infusion 2, respect- 
tively. 
2.5. Human Anti-Human Antibody (HAHA) 
Response 
HAHA reactivity was assessed using a BIACORE assay 
as described previously [34]. Briefly, the highly sensitive 
assay monitors binding to immobilized IGN311 and to an 
isotype matched control antibody. A positive HAHA 
response was defined as at least two-fold increase in RUs 
compared to the matched control antibody and an abso- 
lute value > 50 RUs (Relative Response Units).  
2.6. Complement Dependent Cytotoxicity (CDC) 
Briefly, LeY positive SKBR3 tumor cells were labeled 
with 4  (Amersham, Germany), washed and in- 
cubated for 60 minutes at 37˚C with serial dilutions of 
patient sera, thereby using the patient’s complement. Re- 
lease of 51Cr from lysed target cells into the supernatant 
of the samples was measured using a gamma-counter 
(Cobra 5005, Canberra-Packard, Australia). Cytotoxicity 
was calculated as published [23].  
51
2Na CrO
2.7. Antibody Dependent Cellular Cytotoxicity 
(ADCC) 
Briefly, LeY positive SKBR3 tumor cells were labeled 
with 4  (Amersham, Germany), washed and 
plated together with 5% heat inactivated serum samples 
into 96-well microtiter plates. Effector cells derived from 
peripheral blood mononuclear cells from a healthy vol- 
unteer donor were freshly prepared and added to the tar- 
get cells at an effector to target (E:T) ratio of 40:1. Re- 
lease of 51Cr from lysed target cells into the supernatant 
of the samples was measured using a gamma-counter 
(Cobra 5005, Canberra-Packard, Australia). Cytotoxicity 
was calculated as published [23].  
51
2Na CrO
2.8. Determination of Disseminated Tumor Cells 
in Blood 
Approximately 28 ml blood was collected on day 1 and 
day 15 before start of infusion and on day 43, respect- 
tively. Detection of circulating tumor cells in blood was 
performed by Immunicon Inc. (Enschede, the Nether- 
lands) using a FDA approved method [28-30] based on 
the magnetic enrichment of EpCAM-positive cells which 
are subsequently stained with anti-cytokeratin antibodies.  
3. Results 
Twelve pts (11 male, 1 female) with biopsy proven LeY 
positive tumors were included in the clinical study at the 
II. Medical Klinik, Klinikum Augsburg, Germany. The 
characteristics of the enrolled pts are listed in Table 1. 
3.1. Safety and Tolerability 
Treatment cohorts I and II with three pts each received 
50 mg or 100 mg IGN311, respectively, and did not 
show any drug related adverse events. Within cohort III 
(200 mg dose) the third patient (pt 9) experienced drug 
related adverse events with grade 3 (according to NCI 
CTC) nausea/vomiting after both administrations of 
IGN311. Therefore, according to the protocol two addi- 
tional patients were recruited at this dose group. After the 
reporting of the first SAE (nausea) classified as “prob-
able drug related” with moderate severity in pt 11 (re-
ceiving only one 200 mg infusion) the study protocol was 
amended regarding an increase of the infusion time from 
2 to 4 hours (based on the assumption that toxicities were 
induced by peak levels of IGN311 in the blood). Because 
of the occurrence of adverse events such as vomiting, 
dyspepsia and nausea in pt 12 rated as possibly drug re- 
lated it was indicated that the MTD had been exceeded. 
From the data of the 200 mg dose group nausea and 
vomiting (NCI CTC grade 3) were regarded as dose lim- 
iting toxicities and the 100 mg dose level was defined as 
the maximal tolerated dose in the absence of pre-medi- 
cation (see Table 2). 
Four pts (with 5 reported SAEs) experienced serious 
adverse events (urethral obstruction and rectal bleeding 
in pt 2; death due to tumor progression in pts 8 and 10, 
hospitalization for observation because of vomiting in pt 
11, see Table 3). The SAEs of pts 2, 8 and 10 had ap- 
parently no relationship with the drug but were disease 
related. Pts 8 and 10 died during therapy—the death was 
disease related. The SAE of pt 11 (Cohort III) was classi- 
fied as “probable related” to the study drug with moder- 
ate severity. Twenty minutes after start of infusion vom- 
iting and the symptom hypotension (90 mm Hg) set on 
and the infusion was interrupted for 2 hours after which 
the hypotension resolved.  
Only one laboratory deviation was classified as a pos- 
sibly drug-related adverse event in pt 11: the lipase value 
increased asymptomatically up to 929 U/L two days after 
application of IGN311. All other laboratory deviations 
were classified as related to the underlying cancer dis- 
ease.  
3.2. Pharmacokinetics 
Nine pts were assessable for pharmacokinetic analysis 
after the 1st and 2nd infusion of IGN311. Whereas all pa- 
tients of the 50 mg and 100 mg dose groups were avail- 
able for analysis, in the 200 mg dose group serum sam- 
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ples from only a limited number of pts (n = 3) were 
available. Pt 11 showed adverse drug reactions during the 
first infusion of IGN311 causing interruption of the infu- 
sion for 2 hours and finally withdraw the consent for the 
second infusion. Consequently the results of pt 11 were 
excluded from the final calculation. The results are listed 
in Table 4. Peak serum concentrations were measured 30 
minutes after each infusion and were found to decrease 
over time (Figure 1(a)). The t1/2 after the 1st infusion 
was in accordance with concentrations observed in toxi- 
cological studies with IGN311 in rhesus monkeys with 
up to 10 days for the 50 mg dose and up to 12 days for 
the 100 and 200 mg dose. Mean peak serum concentra- 
tions of IGN311 were in the range of 8 µg/ml for 50 mg, 
17 µg/ml for the 100 mg and 52 µg/ml for 200 mg 
IGN311 dose. AUC0-t values ranged from 892 for 50 mg, 
2711 for 100 mg to 5879 for 200 mg IGN311. T1/2 after 
the 2nd infusion was 13, 24 and 21 days for the 50, 100 
and 200 mg dose groups, respectively. Mean peak serum 
concentrations ranged from 9 µg/ml (50 mg), 23 µg/ml 
(100 mg) to 71 µg/ml for the 200 mg IGN311 dose group. 
AUC0-t values ranged from 1678, 6549 to 12053 µg/ml·h 
for the 50, 100 and 200 mg dose group, respectively 
(Table 4). The increase of Cmax and the AUC0-t value 
was proportional to the applied dose indicating a linear 
pharmacokinetics (Figure 1(a), Table 4). 
 
Table 1. Age, Sex, Dose, Cohort, Karnofsky performance status, Primary site and site of Metastasis at baseline, prior im-
muno- or hormonal therapy and tumor assessment of all patients of the study. Nine out of 12 pats were assessable for tumor 
assessment. nd = not determined. 












1 78, m 50 I 80 CRC Liver Nil Nil Capecitabine SD 
2 66, m 50 I 70 CRC Liver Nil Nil 
Capecitabine, folinic acid + 5FU 
folinic acid + 5FU + Irinotecan 
PD 
3 52, m 50 I 90 GC  Nil Nil folinic acid + 5FU SD 




Adriamycin + Cyclophosphamid 
+ Paclitaxel 
SD 
5 62, m 100 II 80 CRC Liver, lung Nil Nil 
Oxaliplatin+ folinic acid + 5FU 
Capecitabine 
folinic acid + 5FU 
folinic acid + 5FU +Irinotecan 
folinic acid + 5FU + Irinotecan 
PD 




Oxaliplatin + folinic acid + 5FU 
Irinotecan + folinic acid + 5FU 
Neoadj. RCT ARO-Protokoll 
(Radiatio + 5FU) 
PD 
7 62, m 200 III 80 CRC Liver, Lung Nil Nil 
Oxaliplatin + folinic acid + 5FU 
Capecitabine 
Irinotecan + folinic acid + 5FU 
5FU 
PD 
8 49, m 200 III 70 Pan Liver, Lung Nil Nil Gemcitabine nd 
9 66, m 200 III 90 CRC Liver Nil Nil 
Oxaliplatin + folinic acid + 5FU 
Irinotecan + folinic acid + 5FU 
5FU 
PD 
10 64, m 200 III 80 CRC Liver Nil Nil 
Oxaliplatin + folinic acid + 5FU 
5FU 
nd 
11 66, m 200 III 100 CRC Liver, Lung Nil Nil 
Oxaliplatin + folinic acid + 5FU 
Irinotecan + folinic acid + 5FU 
nd 
12 65, m 200 IV 100 CRC Lung Nil Nil 
Oxaliplatin + folinic acid + 5FU 
Capecitabine 
Irinotecan + folinic acid + 5FU 
folinic acid + 5FU 
SD 
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Table 2. Adverse Events (AE) grouped by severity, preferred term, medication applied and the outcome are shown. Severity 
was graded according to common toxicity criteria (CTC). Relationship to study drug was assigned: 1 = unlikely; 2 = possible; 
3 = probable. 
Pt Dose Severity Serious Relationship Preferred Term Medication to treat AE Outcome 
1 50 1 No 1 Hyperuricaemia none n.a. 
1 50 2 No 1 Epistaxis none n.a. 
2 50 1 No 1 Tachycardia none n.a. 
2 50 3 Yes 1 Acute urethral syndrome none n.a. 
2 50 3 Yes 1 Hemorrhage rectum none n.a. 
2 50 nd No 1 Urinary tract infection none n.a. 
6 100 nd No 1 Back pain none n.a. 
7 200 2 No 1 Ascites none n.a. 
7 200 1 No 1 Hyperuricaemia none n.a. 
8 200 3 Yes 1 Condition aggravated none n.a. 
9 200 3 No 2 Vomiting Dimenhydrinat Ondansetron Resolved 
9 200 2 No 2 Coughing Codein Resolved 
9 200 3 No 2 Vomiting Ondansetron Granisetron Resolved 
9 200 2 No 2 Saliva increased Dimetinden Resolved 
10 200 3 Yes 1 Condition aggravated   








12 200 2 No 2 Vomiting Prednisolon Resolved 
12 200 2 No 2 Dyspepsia Dimetinden Resolved 
12 200 1 No 2 Nausea None Resolved 
 
Table 3. Serious adverse events (SAE). 
Pt Adverse event Date of onset Date ended Severity Relationship Treatment Outcome 
2 Urethral obstruction 08.05.03 09.05.03 3 unlikely local recovered with sequelae
2 Rectal bleeding 15.06.03 16.06.03 3 unlikely local recovered with sequelae
8 
Cardio-respiratory failure, disease 
progression 
01.09.03 01.09.03 3 unlikely none patient died 
10 
Acute heart failure, disease 
progression 




17.02.04 23.02.04 2 probable hospitalization recovered 
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3.3. Complement Dependent Cytotoxicity (CDC) shortly after the first and second application. For the 50 
mg dose group the CDC activity returned to baseline at 
the end of the study. In contrast, at the two higher dose 
groups of 100 mg and 200 mg, respectively, CDC activ-
ity remained above background at all time-points of the 
study (up to 43 days which was defined as the end of the 
study) and was in accordance with IGN311 titers. 
CDC data are shown as percentage of specific lysis of 
LeY positive SKBR3 target cells. Significant CDC activ-
ity was measured in the pts serum in all three dose 
groups (Figure 1(b)). The kinetics of CDC activity were 
found to follow the pharmacokinetics measured for 
IGN311 in the pts sera (Figure 1(a)), with peak activities 
 
 
Figure 1. Pharmacokinetics and Pharmacodynamics. Three pts per dose level (*also in cohort III)) were assessable for PK 
and PD analysis of IGN311. Blood samples were taken before and 0.5, 4, 8, 24 hours after start of infusion, and on days 3, 5 
and 8 after the first and second infusion. Additional blood samples were taken on days 29 and 43. Infusion time points at day 
1 and day 15 are indicated as red arrows. Panel (a): Concentrations of IGN311 in the serum were measured using a specific 
sandwich ELISA with mAb MMA383 which specifically recognizes the idiotype of IGN311. Pharmacokinetic parameters 
were calculated separately for each of the two infusions. Panel (b): CDC was measured using the breast cancer cell line 
SKBR3 as target cell line and the patient sera as complement source. Blood samples were taken before and 0.5 hours after 
start of infusion, on days 8 after the first and second infusion, and on days 29 and 43. Panel (c): ADCC was measured using 
the breast cancer cell line SKBR3 as target cell line and PBMCs of healthy donors as effector cells (effector to target ratio of 
40:1). Blood samples were taken before and 0.5 hours after start of infusion, on days 8 after the first and second infusion, and 
on days 29 and 43. 
Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN311 766 
 
3.4. Antibody Dependent Cellular Cytotoxicity 
(ADCC) 
ADCC data are shown as percentage of specific lysis of 
LeY positive SKBR3 target cells after incubation with 
(heat inactivated patient derived) serum and effector cells 
derived from PBMCs from a healthy donor at an E:T 
ratio of 40:1 (Figure 1(c)). The kinetics of ADCC activ-
ity were found to follow the pharmacokinetics data mea- 
sured for IGN311 in the pts sera (Figure 1(a)), and was 
in accordance with the kinetics of CDC activity (Figure 
1(b)) with peak activities shortly after the first and sec- 
ond application. 
3.5. Human Anti-Human Antibody (HAHA) 
Response 
First infusion of IGN311 induced a HAHA response (de-
fined as at least two-fold increase in RUs and absolute 
value > 50 RUs) in six out of 12 pts. Onset of the HAHA 
response was detectable at day 7 and peak levels were 
reached before the second infusion at day 15 (Figure 2). 
Importantly, the second application did not further in-
crease HAHA titers but rather the HAHA response de-
creased. 
3.6. Disseminated Tumor Cells (DTCs) in Blood 
Because disseminated tumor cells are the anticipated 
target of an IGN311 therapy, the blood of patients was 
analyzed for DTCs using antibodies specific for EpCAM 
—a marker frequently expressed on cells of epithelial 
origin, but absent on blood cells. EpCAM positive cells 
(i.e. indicative for DTCs) were found in the peripheral 
blood in two out of twelve pts at day 1 before treatment. 
Notably, in both patients (pt 5 from the 100 mg dose 
group, and pt 7 from the 200 mg dose group) the num-
bers of DTCs were reduced after two applications of 




Figure 2. HAHA response was assayed using SPR (BIAcore). Relative response units (RUs) obtained with patient sera are 
shown. The straight dotted line indicates the response obtained with 1 µg/ml of the IGN311 anti-id antibody MMA383. 
 
 
Figure 3. Number of disseminated tumor cells (DTC) detected in 7.5 ml blood of each patient before the 1st and 2nd application 
of IGN311 and at the end of study. EpCAM positive cells were magnetically enriched and subsequently stained with anti- 
cytokeratin antibodies and counter-stained with anti-CD45 antibodies confirming the epithelial origin of selected cells. 
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3.7. Tumor Assessment 
Only nine out of 12 pts were evaluable for tumor as- 
sessment at the end of the study. Of these nine pts, four 
pts (1, 3, 4 and 12) showed a stabilization of disease ac- 
cording to RECIST and 5 pts (2, 5-7 and 9) showed pro- 
gressive disease (Table 1).  
4. Discussion 
This Phase I dose escalation study demonstrated that 
IGN311 administered twice at biweekly intervals was 
well tolerated at doses up to 100 mg. The MTD of IGN311 
was found to be exceeded at 200 mg with NCI-CTC 
grade 3 nausea and vomiting being dose limiting. Fur- 
thermore, drug related adverse reaction like hypotension, 
coughing, hypersalivation and heartburn were found in 
the 200 mg cohort but were successfully treated with 
appropriate medication. It should be noted that no pre- 
medication was given. In earlier clinical trials, the paren-
tal murine mAb ABL 364 displayed similar toxicities 
already at lower dose levels [17-19]. The increase of the 
infusion time from 2 to 4 hours for pt 12 (second infusion) 
did not change DLT. Glucocorticoids, antihistamines and 
serotonin (5HT3) antagonists were successfully applied 
in case of grade 2 or grade 3 DLT (nausea and vomiting). 
Grade 1 toxicities of vomiting and nausea resolved without 
any treatment. Notably, treatment with IGN311 did not 
result in any hematological toxicity. With the exception 
of pt 11 (in the 200 mg dose group) who showed an as- 
ymptomatic increase in the lipase values (rated as a 
symptom of a drug-related adverse event) all other devia- 
tions of laboratory parameters were classified as related 
to the underlying cancer disease. 
The fully humanized mAb IGN311 has shown a fa- 
vorable serum half-life in this study with a t1/2 of 10 - 12 
days after the first infusion and of ~20 days following the 
second infusion of 100 mg IGN311/patient, being close 
to the reported t1/2 of 21 days of natural IgG and other 
therapeutic anti-tumor mAbs like Rituximab or Trastu- 
zumab [35,36] (Figure 1(a), Table 4). Regarding the 
patient’s safety, monitoring of the induction of HAHA 
responses is important and also recommended by the 
FDA. A BIACORE-based assay was applied that is able 
to also detect weak HAHA responses [34]. After IGN311 
application, HAHA reactivity was detected in six out of 
12 pts defined by an at least two-fold increase in RUs 
over pre-serum values and the absolute values being >50 
RUs. Because no increase of binding to the isotype mat- 
ched control antibody was observed it can be concluded 
that the observed HAHA response has been directed 
against the specific binding regions of IGN311. 
With the exception of one study [37] clinical trials 
with humanized mAbs have so far not reported such 
high incidence of HAHA responses—e.g. application of 
CAMPATH (anti-CD52 humanized Ab, Alemtuzumab) 
[38] or Herceptin (humanized anti-HER2 mAb) [39] was 
reported to induce almost no HAHA responses after i.v. 
application (0 out of 30) or (1 out of 211), respectively. It 
has to be stressed here that these studies applied ELISA 
based techniques therefore using a different detection 
system than applied in the current study. The BIACORE 
—surface plasmon resonance—based method monitors 
HAHA binding in real time without the need of a secon-
dary, enzyme-labeled detection antibody and is therefore 
capable to detect low affinity antibodies which results in 
improved sensitivity. Within the present study, 50% 
HAHA positive patients were identified which is in ac- 
cordance with results published by Ritter et al. using a 
similar detection system [37]. Regarding the detected 
anti-drug antibodies it should be noted that the SPR- 
based Biacore method is generally more sensitive than 
ELISA because with ELISA low-affinity antibodies can 
hardly be detected [40]. 
 
Table 4. Pharmacokinetic parameters were calculated for each dose level, separated for 1st and 2nd infusion. Only three out of 
six pats of the 200 mg dose level group were evaluable for pharmacokinetic analysis. 













Parameter Unit (n = 3) (n = 3) (n = 3) (n = 3) (n = 3) (n = 3) 
AUC 0-t µg/ml·h 891 1677 2711 6549 5878 12053 
cmax µg/ml 7.9 9.3 16.5 22.9 51.7 71.0 
kel h –0.003 –0.004 –0.002 –0.001 –0.003 –0.001 
t1/2 h 250 304 289 571 298 504 
AUC ∞ µg/ml·h 1474 3025 4825 11304 10657 18707 
last value µg/ml 1.6 3.2 4.9 5.8 9.5 9.5 
% AUC extrapolated % 38 56 42 42 38 37 
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Importantly, with regard to the therapeutic potential, 
sera of patients receiving IGN311 were capable of lysing 
LeY positive tumor cells ex vivo by both, CDC and 
ADCC. Whereas IGN311 has been also shown to block 
signal transduction through LeY glycosylated growth 
factor receptors such as EGFR and Her2-neu on tumor 
cells [24,41], the effector functions mediated by this fully 
humanized antibody, i.e. CDC and ADCC may be con-
sidered to be pivotal for the anticipated anti-tumor effects 
of IGN311 in vivo. 
Regarding anti-tumor efficacy, EpCAM positive cells 
in the peripheral blood—indicative for DTC’s—detect- 
able in two out of twelve patients (pts 5 and 7) before 
treatment—were eliminated after treatment to below the 
quantification limit of the detection method. Cristofanilli 
et al. [28-31] have shown that DTC’s in peripheral blood 
of pts with breast cancer are of prognostic significance 
and can be used as a surrogate parameter for therapeutic 
efficacy of anti-cancer therapy. In recent publications, 
the concept of CTC’s as prognostic factor for metastatic 
disease has been confirmed. Krebs et al. [42] demon-
strated that in patients with Non-Small-Cell Lung Cancer 
(NSCLC) progression-free survival inversely correlates 
with the amount of detectable CTC’s. This is in accor-
dance with Tanaka et al. [43] who showed that in lung 
cancer patients, CTC counts significantly increased along 
with tumor progression, especially with development of 
distant metastasis. For breast cancer, Pachmann et al. [44] 
showed that an increase of circulating epithelial tumor 
cells was a strong indicator for a relapse. In summary, 
the isolation and characterization of individual tumor 
cells from the blood of patients known to have metastatic 
cancer hold tremendous potential for new biological in-
sight with very real clinical applications [45]. Tradition-
ally, CTC’s are isolated using the well-characterized sur- 
face molecule EpCAM that is expressed on various epi- 
thelial tumors [46]. Therefore, the recovery/detection 
might be improved if a combination with additional tu-
mor cell markers is applied [47,48]. 
5. Conclusions 
The assessment of tumor markers and objective tumor 
responses by RECIST criteria did not reveal clear results. 
First hints for an in vivo anti-tumor activity of IGN311 
are the induced ex vivo effector functions and the disap-
pearance of detectable DTCs in peripheral blood (evident 
after only two applications). It is the opinion of the au-
thors that the therapeutic potential of IGN311 may pri-
marily reside in eliminating DTC’s cells and microme-
tastases thereby preventing progression of disease, rather 
than in direct effects on bulky tumors which are prefera-
bly removed by surgery. Possibly, the application of 
IGN311 in an adjuvant, neoadjuvant or perioperative 
setting, or in combination with additional treatment mo-
dalities, e.g. radiotherapy and chemotherapy, may finally 
translate into a significant improvement in patients dis-
ease status and long term survival of the patients. Based 
on the presented data further clinical (Phase II) testing of 
IGN311 in a metastatic disease set-up is planned. 
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